An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

We report a HER2(T798I) gatekeeper mutation in a patient with HER2(L869R)-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2(L869R) is a neratinib-sensitive, gain-of-function mutation that upon dimerization with mutant HER3(E928G), also present in the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Hanker, Ariella B., Brewer, Monica Red, Sheehan, Jonathan H., Koch, James P., Sliwoski, Gregory R., Nagy, Rebecca, Lanman, Richard, Berger, Michael F., Hyman, David M., Solit, David B., He, Jie, Miller, Vincent, Cutler, Richard E., Lalani, Alshad S., Cross, Darren, Lovly, Christine M., Meiler, Jens, Arteaga, Carlos L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457707/
https://ncbi.nlm.nih.gov/pubmed/28274957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1431
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados